ACL Inhibitor Modulation of Stem Cell Pluripotency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively maintain pluripotency and self-renewal properties of stem cells, as they do not adequately address the metabolic diversity and cell-state specific metabolic networks, particularly the engagement of the tricarboxylic acid (TCA) cycle in regulating cell fate transitions.
Innovation Solution
Blocking the non-canonical TCA cycle using ATP citrate lyase (ACL) inhibitors or acetate prevents stem cells from exiting the pluripotent state by manipulating the TCA cycle configuration, which is critical for cell-state transitions, employing specific ACL inhibitors like BMS-303141 or natural inhibitors such as (−)-hydroxycitric acid, and contacting cells with these agents at optimal concentrations and durations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to maintain stem cells, then general cell culture is achieved, but pluripotency and self-renewal properties are not effectively maintained
Solution Approach 1:
The patent changes the metabolic parameter of the TCA cycle by blocking the non-canonical pathway using ACL inhibitors or acetate. This parameter change prevents stem cells from exiting pluripotency by maintaining the canonical TCA cycle configuration, thereby reliably maintaining pluripotency and self-renewal properties while accounting for metabolic diversity.
2Reliability
If the non-canonical TCA cycle is blocked using ACL inhibitors, then pluripotency is maintained, but cell metabolic flexibility is reduced
Solution Approach 1:
The patent extracts or removes the non-canonical TCA cycle pathway from active metabolism by blocking ACL enzyme activity. This selective removal of the alternative metabolic pathway prevents pluripotency exit while the cells retain the canonical TCA cycle, thereby maintaining pluripotency with controlled metabolic flexibility.
3Productivity
If stem cells are allowed to undergo lineage commitment, then differentiation is achieved, but pluripotency is lost
Solution Approach 1:
The patent applies preliminary anti-action by blocking the non-canonical TCA cycle before lineage commitment can occur. By preventing the metabolic shift associated with differentiation through ACL inhibition, the method counteracts the natural progression toward lineage commitment, thereby maintaining pluripotency while controlling differentiation timing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach maintains pluripotency and self-renewal properties of stem cells by preventing the transition from a canonical to a non-canonical TCA cycle, ensuring cells remain in a pluripotent state, as demonstrated by the prevention of exit from naïve pluripotency and maintenance of alkaline phosphatase-positive colonies.
Implementation Method 1
blocking the non-canonical TCA cycle comprises contacting the cells with an ATP citrate lyase (ACL) inhibitor
Data Source
AI summary
The present disclosure relates to methods for modulating (e.g., maintaining) pluripotency and self-renewal property of cells (e.g., stem cells) by blocking the non-canonical tricarboxylic acid (TCA) cycle (e.g. using an inhibitor of ATP citrate lyase (ACL) or acetate), and kits and compositions relating thereto.